The Human Papillomavirus (HPV) E4 is known to be synthesized as an E1^E4 fusion resulting from splice donor and acceptor sites conserved across HPV types. Here we demonstrate the existence of 2 HPV-18 E2^E4 transcripts resulting from 2 splice donor sites in the 5 0 part of E2, while the splice acceptor site is the one used for E1^E4. Both E2^E4 transcripts are up-regulated by keratinocyte differentiation in vitro and can be detected in clinical samples containing low-grade HPV-18-positive cells from Pap smears. They give rise to two fusion proteins in vitro, E2^E4-S and E2^E4-L. Whereas we could not differentiate E2^E4-S from E1^E4 in vivo, E2^E4-L could be formally identified as a 23 kDa protein in raft cultures in which the corresponding transcript was also found, and in a biopsy from a patient with cervical intraepithelial neoplasia stage I-II (CINI-II) associated with HPV-18, demonstrating the physiological relevance of E2^E4 products.
Introduction
In the HPV compact and short (8 kb) circular genome, the 3 reading frames serve as coding sequences, with overlaps between the different genes and extensive use of alternative splicing. The E2 open reading frame (ORF) encodes both E2 and E4 in different frames, a situation found to be conserved in all sequenced HPV genomes. In HPV-16, the E4 protein has been shown to be expressed as a fusion product between the 5 0 aminoterminal residues of E1 and the full-length E4, translated from a spliced mRNA obtained from a splice donor site in E1 and a splice acceptor site in E2 at the beginning of the E4 ORF (Doorbar et al., 1986 (Doorbar et al., , 1990 . For this reason, the E4 protein is referred to as E1^E4. With the exception of E6*^E4 mRNA, found in W12 cells expressing episomal copies of the HPV-16 genome (Milligan et al., 2007) , no other fusion of HPV-16 E4 with other viral proteins has been described in the literature to day and it is therefore accepted that the HPV-18 E4 protein is similarly exclusively expressed as an E1^E4 fusion product. The HPV-16 E1^E4 fusion protein, which has been better described than the HPV-18 E1^E4, is a strictly cytoplasmic protein with multiple functions. It is expressed in the intermediate and upper layers of the infected epithelia, and has been shown to lead to reorganization and degradation of the keratin intermediate-filament network, presumably to favor production of viral particles (Doorbar et al., 1991; McIntosh et al., 2010) . It can activate apoptosis through its cytoplasmic localization at mitochondria (Raj et al., 2004) , and is able to arrest the cell cycle in G2, presumably to create a pseudo S-phase that optimizes conditions for viral DNA replication (Davy et al., 2002) .
In addition to a role in viral DNA replication, the HPV E2 protein has been shown to repress E6 and E7 transcription and, in HPV-18-associated cancers, to be disrupted by integration of the viral genome into the cellular genome (Demeret et al., 1998; Kraus et al., 2008; Thierry and Yaniv, 1987) . Recently, several unexpected functions of the high-risk HPVs (HPV-types able to induce cancer as opposed to low-risk types which induce only benign lesions) E2 proteins have been described. These new functions include regulation of apoptosis and cell cycle by both high-risk HPV-18 and HPV-16 E2 proteins Blachon et al., 2005) . Also, HPV-16 E2 and E1^E4 proteins have been shown to interact with each other leading to re-localization of E2 with E1^E4 in cytoplasmic speckles, and their co-expression has been shown to lead to the reciprocal stabilization of the proteins (Davy et al., 2009 ).
Here we show that the HPV-18 E2 gene can generate 2 different E2^E4 proteins, one short (S) and one long (L), resulting from alternative splicing between 1 of a possible 2 splice donor sites in the 5 0 part of the E2 gene, and the classical splice acceptor site before the E4 gene, used for E1^E4 splicing. These 2 spliced transcripts and proteins could first be detected in cells infected by recombinant adenoviruses expressing HPV-18 GFP-E2 (AdGFP-18E2), and were then found in keratinocytes transfected with the HPV-18 genome, in which they were up-regulated by differentiation. Finally, detection of the 2 transcripts in 4 independent HPV-18-positive Pap smear clinical samples, as well as detection of the E2^E4-L protein in HPV-18 raft cultures and a HPV-18 CIN I-II clinical sample, provide evidence of the physiological relevance of these new viral gene products in the HPV-18 model.
Results
The HPV-18 GFP-E2-recombinant adenovirus expresses GFP-E4-containing proteins Through GFP-E2 Tap-Tag experiments and by mass spectrometry analyses, we found E4 peptides fused to GFP in AdGFP-18E2 infected cells (data not shown). Since the cell line used was HPV-negative, the E4 peptides must have been produced from the E2 expression vector. Indeed, immunoprecipitation against GFP followed by western-blots with extracts from C33 cells infected with AdGFP-18E2, showed not only the presence of the GFP-E2 protein (shown by arrow in Fig. 1A ), but also other GFP products among which 2 proteins (around 40 and 50 kDa), also revealed by the E4 antibody (labeled by asterisks in Fig. 1A ). The lowest band on the anti-E4 western-blot, is not present in each experiment and is probably a degradation product of one of the 2 upper E4 products. Extract from cells infected by AdGFP was used as a control and does not show any specific E4-containing product. Two alternatively spliced E2^E4 fusion transcripts are encoded by the E2 gene
We amplified the transcripts encompassing the E2 ORF produced in AdGFP-18E2 infected cells using a forward primer [GFPf] localized at the 3 0 end of the GFP gene, and a reverse primer [DBDr] at the 3 0 end of E2 (Fig. 1B) . The major product of 1200 bp corresponded to the full-length HPV-18 E2, while the sizes of the 2 main other products around 950 bp and 650 bp (shown by asterisks; Fig. 1B ), had compatible coding capacity for the 2 fusion proteins described in Fig. 1A . Sequencing of these 2 cDNAs showed that they do encode fusion proteins containing GFP followed by 2 different amino-terminal parts of E2 (nucleotides 1-37 and 1-349) fused to the full-length E4, as depicted in Fig. 1C . These fusion proteins are therefore translated from alternative spliced RNAs using two splice donor sites downstream of GFP in the 5 0 part of the E2 gene (nucleotides 2853 and 3165), which are consensus sequences AAGTG and AGGTG (Fig. 5B) . The 2 different E2^E4 transcripts encode proteins of 95 (E2^E4-S, expected molecular weight [MW] around 11.5 kDa) and 199 amino-acids (E2Ê 4-L, 23 kDa), which are equivalent to MWs of 38.5 kDa and 50 kDa respectively when fused to GFP. We further confirmed the role of the E4 acceptor splice site by mutating it in the GFP-E2 expression vector. For this, we substituted the S residue at position 206 to A (E2DS). As shown in Fig. 1D , the mutated sequence prevented synthesis of the 2 GFP-E2^E4 proteins in the transfected HeLa cells.
Design of specific primers to detect the E2^E4-S and E2^E4-L mRNAs by Real-Time PCR
In this work we used couples of primers specific for each of the 3 spliced junctions (E1^E4, E2^E4-S and E2^E4-L). The reverse primer targeted a downstream common sequence in E4 and the different forward primers overlapped the sequences of the donor and acceptor sites. Because of this overlap, the E2^E4-S and L forward primers contained adjacent E2 and E4 sequences, and we had to verify the specificity of their hybridization to E2^E4-S and L compared to their hybridization to E2 and E1^E4. This was addressed by direct Real-Time PCRs (RT-PCR) on template plasmidic DNAs ( Fig. 2A) . We compared the Cts (cycle threshold) values obtained with the 2 sets of E2^E4 primers after PCR using their own template or E2 and E1^E4 templates. The E2^E4-S and E2^E4-L sets of primers produced differences in amplification (characterized by DCts) between the non-specific and specific templates of at least 8 (20 compared to 28) and 9 (22 compared to 31) for E2^E4-S and E2^E4-L respectively. These differences correspond to a specificity of 99.6% for E2^E4-S primers and 99.8% for E2^E4-L primers. The level of specificity was calculated by the formula 100 À[100 Â (1/2 DCt )]. We deduced from these calculations that the ratios E2^E4/E1^E4 and E2^E4/E2 mRNAs must be 40.4% for E2^E4-S and 40.2% for E2^E4-L to be significant, and all experiments presented in this study fulfilled these requirements. Sequences of primers used are given in Materials and methods.
The E2^E4 mRNAs are detected in HPV-18-positive clinical samples containing Pap smears cells
To look for E2^E4 transcripts in clinical samples, we first studied 5 independent Pap smear samples collected from 5 patients, 4 presenting low grade HPV-18 lesions (patients #1, 2, 3 and 4), and 1 presenting a low-grade HPV-58 lesion (patient #5, which we used as a negative control). The HPV genome in infected cells from these samples was most likely episomal since we could amplify the E2 transcripts (Fig. 2B) , which would not have been possible if the HPV genome was integrated into the E2 ORF as often occurs in HPV-18 clinical samples (Kraus et al., 2008) . However, we cannot exclude integration in a small minority of cells. We investigated the relative expression of the E2^E4 transcripts compared to E1^E4 and E2 in RT-PCR on total RNA using the primers described above. All data are normalized with 18S RNA, and the graph presents values further standardized to the E1^E4 RNA amplification of patient #4. The 2 E2^E4 spliced transcripts were detected in high quantity in the 4 HPV-18-positive clinical samples when compared to the E1^E4 transcripts, which were surprisingly low in all the samples. However, significant variations in transcripts levels were seen from one sample to the next, although unspliced E2 transcripts exhibited comparable levels to the spliced transcripts in individual samples (Fig. 2B) . These experiments led us to conclude that the 2 E2^E4 spliced products are expressed in vivo and to hypothesize that they may be actively expressed in scrapped cells from low grade HPV-18-associated lesions due to terminal differentiation of these cells.
Levels of the two E2^E4 spliced transcripts increase during keratinocyte differentiation
To elucidate whether expression of the E2^E4 spliced transcripts could be modulated by keratinocyte differentiation, we studied their levels in an in vitro differentiating system. We used the n-TERT keratinocyte cell line, which is immortalized by hTERT (Dickson et al., 2000) and can differentiate in vitro if grown in RMmedium. Differentiation was followed for 5 days by testing the induction of involucrin and keratin 13, 2 markers of keratinocyte terminal differentiation. After 5 days of differentiation, the global shape of the cells changed from small cuboid cells, when not differentiated (in KGM medium), to large strongly clustered cells when differentiated in RM-medium (Fig. 2C , left and middle panels). Concomitantly, levels of involucrin and keratin 13 were elevated by the change of medium as shown by western-blot ( Fig. 2C , right panel). The total RNA from n-TERT cells transfected by the HPV-18 genome was analyzed 5 days after induction of differentiation, or after 5 days of culture in KGM medium as a control (Fig. 2D , upper panel). All RT-PCR values were normalized with 18S RNA, and the graph presents values standardized with the value of E1^E4 transcripts amplification in KGM set to 1 (Fig. 2D ). Transcription of keratin 13 (K13) was used as a positive control for differentiation. The levels of E2^E4-S and E2^E4-L transcripts increased by 2.9 and 4.5-fold respectively in differentiated cells, while the E1^E4 and E2 spliced mRNA were not significantly modulated (Fig. 2D , upper panel). Both E2^E4 alternatively spliced transcripts therefore appeared augmented by keratinocyte differentiation, although their levels still remained lower than E1^E4 levels, contrasting with Pap smear results. This discrepancy could either be due to transcriptional activation, stabilization of mRNA or activation of alternative splicing in cells from Pap smears. More work is needed to elucidate as to which is operating in this case.
The E2^E4-L protein is expressed in HPV-18 raft cultures and in a CINI-II lesion
The HPV viral cycle can be recapitulated in vitro in 3D keratinocyte raft cultures, which mimic epithelia structures, allowing HPV DNA replication. We used these raft cultures to check for the expression of the E2^E4 spliced transcripts and proteins in more physiological conditions as compared to monolayer cultures. In sections of paraffin embedded HPV-18 rafts, we could identify expression of E2-containing proteins by immunohistochemistry together with viral DNA replication by in situ hybridization (ISH). They occur in the same upper-intermediate layers ( Fig. 3A ; left panel), as we recently showed the HPV-16 E2 protein to be localized in clinical samples containing low-grade CIN lesions (Xue et al., 2010) . Detection of E4 expression in an adjacent section of the same raft culture showed its expression in intermediate and upper layers, overlapping E2 expression ( Fig. 3A ; right panel). However, since we could not distinguish the spliced E2^E4 products from E2 and E1^E4 in the immunolabeling, we performed a western-blot analysis of raft culture extracts. The E2^E4-L protein, with an expected molecular weight of 23 kDa, could be detected by western-blot analyses using the HPV-18 E4 antibody as shown in Fig. 3B ; left panel; raft lane. Another more abundant E4 protein with a MW of around 10 kDa could also be detected, which could correspond to the E1^E4 or/ and E2^E4-S products. Real-time PCR analyses of the transcripts from an adjacent paraffin embedded section of the HPV-18 raft compared to that of a normal raft, showed that the E2^E4-L transcript was expressed ( Fig. 3B; right panel) , thereby validating the western-blot data. In contrast, transcripts of the lower MW E2^E4-S isoform were below our defined detection threshold. Therefore, we deduced from these data that in HPV-18 raft cultures, both E2^E4-L transcript and protein can be found, although the main E4 isoform expressed is E1^E4.
We then looked at E2 and E4 expression in a HPV-18 positive CINI-II lesion from a patient biopsy. Immunohistochemistry staining and in situ hybridization showed that expression of E4 overlaps with E2 in the upper-intermediate layers of the lesion, and that viral DNA replication occurs in intermediate layers concomitantly with E2 expression, similarly to the expression pattern in HPV-18-positive rafts (compare Fig. 3A and C) . Interestingly, protein extract of this sample showed expression of the 2 same proteins (23 kDa and 10 kDa) using the anti-E4 antibody ( Fig. 3B ; left panel; lesion lane). This confirms the presence of the E2^E4-L product together with E1^E4 in a HPV-18-positive CIN lesion. Attempts to analyze the transcripts were unsuccessful due to poor quality of the RNA sample. In conclusion, data on E2^E4 expression in HPV-18 rafts and CIN confirm the existence of the E2^E4-L product, although the E2^E4-S protein and mRNA could not be identified. The relative quantities of E2^E4 and E1^E4 in rafts and CIN do not correlate with our previous observation of relative high expression of E2^E4 compared to E1^E4 in smear cells, but do match the in vitro results using differentiation induction in keratinocytes. We have no explanation for this discrepancy at present, other than a difference in the differentiation status of the cells as discussed below. Detection of the E2^E4-L protein and transcript in raft and CIN is a clear indication of a physiological relevance of at least one of the E2^E4 isoforms in vivo.
The two E2^E4 proteins are cytoplasmic and induce cell death
We cloned the 2 spliced cDNAs corresponding to the E2^E4-S and E2^E4-L transcripts fused to GFP in CMV-driven expression vectors and verified the expression and correct sizes of the corresponding proteins by western-blot ( Fig. 4A; left panel) . We then studied the localization of each protein in transfected U2OS cells. Fig. 4A right panel shows that the GFP-E2^E4-S protein is expressed exclusively as cytoplasmic speckles, similar to E1^E4, and partially co-localizes with mitochondria as shown by MitroTracker labeling (Fig. 4B) . The GFP-E2^E4-L protein appears more diffuse in the cytoplasm with some accumulation in dots ( Fig. 4A ; right panel). This protein could also appear more aggregated, depending on cell type, when highly expressed (data not shown). Similar results were obtained with untagged E2^E4 proteins (data not shown). Both the N-terminal domains of E2 (Thierry and Demeret, 2008) and the E1^E4 proteins (Raj et al., 2004) have been shown to induce apoptosis and we decided to verify whether this was also true for the E2^E4 proteins. HeLa cells were transfected for 30 h with expression vectors of GFP-E2, GFP-E2DS, GFP-E2^E4-S or GFP-E2^E4-L and were subjected to propidium iodide (PI) uptake, a method in which only the DNA of dead cells is labeled due to membrane permeabilization. GFP-positive cells were then selected and analyzed for PI labeling by flow cytometry. As previously shown, wild-type E2 expression induces cell death Thierry and Demeret, 2008 ) and here we show that the same is also true for the 2 E2^E4 proteins when compared to GFP expression alone at comparable level (Fig. 4C, left  panel) . In contrast, the E2DS mutant, which expresses only the unspliced full-length E2 (as shown in the western-blot, Fig. 4C ; right panel), showed a reduced level of cell death, despite a higher expression level, when compared to the wild-type expression vector ( Fig. 4C; right panel) . These results indicate that apoptosis, previously solely attributed to HPV-18 E2, could in fact result from additive activities of E2 and E2^E4 proteins when alternative splicing is allowed. This is an important result suggesting a need to use splice-site-defective E2 sequences to study HPV-18 E2 properties in vitro, since E2^E4 could interfere with E2 functions.
The splice donor sites in E2 are conserved in a subset of high-risk HPV types but not in HPV-16
We then examined whether the splice donor sites in the HPV-18 E2 ORF were conserved among other HPVs by comparing the E2 sequences of various genital HPV types. None of the 2 donor sites were found in HPV-16 due to absence of the essential dinucleotide GT (Fig. 5B) , thus corroborating previously published HPV-16 transcription maps (Milligan et al., 2007; Sherman and Alloul, 1992; Zheng and Baker, 2006) . In agreement with absence of alternative splicing in HPV-16 E2 expression vector, we did not detect E2^E4 proteins in cells infected with the recombinant adenovirus expressing HPV-16 GFP-E2 (Fig. 5A) . Interestingly however, the first splice donor (SD1) site, giving rise to the HPV-18 E2^E4-S, is conserved in 4 HPV types from the alpha-7 group (HPV-18, 97, 45 and 59) as well as in HPV-58 and 35, while the second splice donor site (SD2), giving rise to the HPV-18 E2^E4-L protein, is only found in HPV-18 and HPV-97 (Fig. 5B) .
Discussion
We have shown here that new fusion mRNAs and proteins between E2 and E4 (E2^E4-S and E2^E4-L) can be produced by alternative splicing of HPV-18 E2. The 2 splice donor sites are new sites localized at nucleotides 2853 and 3165 in the 5 0 part of the E2 gene which are not described in the recently published HPV-18 transcription map (Wang et al., 2011) . The acceptor site for both spliced products was previously described for E1^E4 (nucleotide 3433). The 2 mRNAs were expressed in cells transfected with the HPV-18 genome, as well as in 4 independent HPV-18-positive Pap smear samples. In raft cultures, only the E2^E4-L transcript could be unambiguously identified, and the corresponding E2^E4-L fusion protein could be detected by western-blot. In the CINI-II lesion, although the extracted RNA quality meant that it could not be analyzed, the E2^E4-L protein could also be identified by western-blotting.
Identification of high levels of E2 expression in intermediate layers of HPV-16 CIN lesions has recently been reported (Xue et al., 2010) , and is consistent with the localization of HPV-18 E2 obtained here in HPV-18 raft cultures as well as in the HPV-18 CIN. In addition, our experiments unambiguously established that E2 and E4 are expressed in the same layers in low grade lesions thus substantiating their potential functional and physical interaction as previously reported (Davy et al., 2009) . These data also indicate that expression of the new E2^E4 proteins could take place in the same region as E2 and E1^E4 do, and could therefore be under similar transcriptional control in low grade lesions in vivo. It should be noted that, although E1^E4 is clearly expressed in differentiated cells of rafts and lesions, and although keratinocyte differentiation induces initiation of transcription at the late promoter of HPV-16 (Grassmann et al., 1996) , it is not fully demonstrated whether the E1^E4 protein is translated from these late transcripts or from early transcripts coming from P97 (HPV-16) and P105 (HPV-18) promoters. Regarding E2, its transcription is thought to be initiated at the early promoter, although this is not sustained by the recent published localization of HPV-16 E2 (and the localization of HPV-18 E2 shown here) in intermediate and upper differentiated layers (Xue et al., 2010) . In fact, E2 localization would rather be in favor of a late transcript of E2 as suggested by Sherman and Alloul (1992) . Taking this into account, it is very difficult to predict the promoter of E2^E4. Like E2, E2^E4 mRNAs could be initiated by the early or late promoter, although expressed in differentiated layers. In any case, expression of E2^E4 in differentiated keratinocytes is consistent with the published localization and expression of both E2 and E1^E4 in the same layers of differentiated keratinocytes, although regulation of their transcription is not clear. This is an important point showing that dark zones exist in knowledge of HPV transcripts, and analysis of the structure and splice regulation of viral RNAs in vivo have to be completed to enable a greater understanding of the process.
In 4 independent samples from HPV-18-positive Pap smears, the 2 spliced E2^E4 transcripts seem to be more abundant than the E1^E4 transcript. The putative role of cell differentiation suggested by these results was confirmed in vitro in HPV-18-transfected keratinocytes where the two E2^E4 transcripts were up-regulated upon differentiation contrary to E1^E4. However, in contrast to Pap smear samples where the E2^E4 transcripts prevail over E1^E4, the levels of E2^E4 mRNAs remain lower than E1^E4 in our in vitro system of HPV-18-differentiated monolayer keratinocytes and in raft cultures. At present we cannot explain this discrepancy but hypothesize that host factors absent in in vitro studies play a role in differentiation of keratinocytes and would ultimately favor E2^E4 transcription or splicing compared to E1^E4. Unfortunately, we cannot test this hypothesis due to rarity of HPV-18-associated CIN lesions and poor quality of RNA extracted from paraffin embedded tissues. Nevertheless, the E2Ê 4-L protein was found in the CIN lesion analyzed indicating that this protein is expressed under physiological conditions.
What are the expected functions of these 2 new E2^E4 fusion proteins? The short E2^E4-S only differs from E1^E4 at its aminoterminus, containing 12 amino-acids of E2 instead of 5 aminoacids of E1. However, in this short E1 sequence, the second and third amino-terminal residues, A and D, conserved between HPV-16 and 18, have been shown to be required, together with the LLXLL motif in E4, for association with keratins (Roberts et al., 1994; Wang et al., 2004) . The same LLXLL motif in E4 is sufficient to mediate E1^E4 mitochondrial localization (Raj et al., 2004) . Since E2^E4-S does not contain the E1 AD sequence, but contains the E4 leucine rich motif, this new fusion protein would be expected to display a preferential mitochondrial localization. When expressed in U2OS, E2^E4-S appears as cytoplasmic speckles partially co-localized with MitoTracker, comparable to the E1^E4 dots characteristic of the mitochondrial localization previously reported (Raj et al., 2004) . We do not detect here the filamentous localization of E1^E4 associated with keratins, which might be due to lower levels of keratins in U2OS cells compared to Cos-7 and SiHa cells used previously (Wang et al., 2004) . We show that the E2^E4-S protein is able to induce cell death in HeLa cells as does E1^E4 (Raj et al., 2004) . The similarities between E1^E4 and E2^E4-S, the lower quantity of E1^E4 mRNA compared to E2^E4-S detected in HPV-18 Pap smears, and the increase of the E2^E4 alternative spliced products during keratinocyte differentiation led us to hypothesize that the E2^E4-S could be an alternative E4 product expressed by the HPV-18 genome in productive lesions. However, this new fusion protein would not be expected to cover all E1^E4 functions such as keratin binding for instance, as discussed above. In contrast to the short E2^E4-S, the long E2^E4-L protein contains a large part of the E2 protein encompassing the 3 amino-terminal a-helices and the fulcrum (rigid linker between the a-helices and b-sheet domains) (Antson et al., 2000) . This protein appears exclusively cytoplasmic, rather diffuse, although it can accumulate into some dots and can aggregate in some cell lines like HeLa when overexpressed. It exhibits cell death-inducing properties when transfected in HeLa cells, a characteristic also shared by E2, E1^E4 and E2^E4-S. It is important to highlight that E2 and E1^E4 are known to interact with each other when co-expressed, leading to delocalization of E2 in cytoplasmic speckles where E1^E4 is primarily localized (Davy et al., 2009 ). It is not surprising that E2^E4-L, which does not contain the E2 nuclear localization domain, exhibits a different localization to E2, which is mainly nuclear with some cytoplasmic speckles . The E2^E4-L fusion protein contains important E2 domains involved in degradation, transactivation, replication, apoptosis induction, and interaction with many cellular proteins including TopBp1, Brd4, caspase 8, APC/C or SCF Skp2 (Bellanger et al., 2001 Boner et al., 2002; Thierry and Demeret, 2008; You et al., 2004) fused to the full-length E4. This fusion could therefore functionally correspond to a natural E2/E1^E4 heterodimer and efficiently mimics the interaction between the two proteins that has been described previously (Davy et al., 2009) .
The discovery of a new cytoplasmic E2^E4-L viral fusion protein, that is restricted to a few HPV types and which is induced by differentiation, opens up new fields for future investigations. Indeed, we believe that it could functionally mimic the E2/E1^E4 interaction (with possibly more potent activities), but could also exhibit new functions that might be important for the HPV-18 viral cycle as well as for HPV-18 pathophysiology.
Material and methods
Cell culture, infection, electroporation and transfection Infections with recombinant adenoviruses (as described in Bellanger et al., 2001) , expressing the Green Fluorescent Protein (AdGFP) and GFP-tagged E2 (AdGFP-E2) were done at a multiplicity of infection (m.o.i.) of 100 (with or without 4 mg/ml of polybrene depending on the cell line), for 1 h in DMEM without FCS. The medium was then replaced by DMEM 10% FCS, and the cells were harvested 24 h later for immunoprecipitation and western-blot analyses.
Immunoprecipitation and western-blot
Cells were infected with AdGFP-18 E2 or AdGFP at m.o.i. 100 for 24 h. Proteins were extracted with an extraction buffer (300 mM NaCl, 0.5% Nonidet P-40, 50 mM Tris-HCl [pH 8], 1 mM EDTA, protease and phosphatase inhibitors) for 30 min at 4 1C, followed by centrifugation at 13000 rpm for 30 min. Extracts containing 1 mg of total proteins were immunoprecipitated using GFP-Trap_A beads (ChromoTek) according to the manufacturer's instructions. Samples were separated by Sodium Dodecyl SulfatePolyAcrylamide Gel Electrophoresis (SDS-PAGE) and analyzed by western-blot. Proteins from the raft and CINI-II lesion were extracted using the Qproteome FFPE Tissue Kit (Qiagen).
For western-blot experiments, anti-GFP (TP401; Torrey Pines Biolabs) and anti-E4 polyclonal antibodies from HPV-18 (McIntosh et al., 2010) or HPV-16 (Doorbar et al., 2000) were used.
PCR and Real-Time PCR
RNAs from HaCat cells were extracted using RNeasy mini kit (Qiagen), treated with DNAase A and converted to cDNA using Transcriptor First Strand cDNA synthesis kit (Roche). PCR was performed on cDNA using GFPf (5 0 agaagcgcgatcacatgg 3 0 ) and DBDr (5 0 aatggatccttacattgtcatgtatcccacc 3 0 ) primers. PCR products were separated on 1% agarose gel and the bands were excised and cloned into pGEM-T easy vector (Promega). DNAs of the positive clones were sequenced using Big Dye v3.1 (Applied Biosystems) and analyzed using ABI-3730xl sequencer (Applied Biosystems).
For Real-Time PCR analyses, RNAs from n-TERT and Pap smears cells from different patients with low grade cervical squamous intraepithelial lesions (LSIL), were extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. All samples were subjected to DNAse A treatment before reverse transcription. For rafts, RNAs were extracted using RNeasy FFPE Kit (Qiagen). Two hundred nanograms of RNA for rafts and between 60 and 150 ng of RNA from Pap smear cells (measured with nanodrop ND-1000) were reversed transcribed for further analyses. For n-TERT cells, 2.5 mg of total RNA measured with nanodrop ND-1000 were reverse-transcribed. Reverse transcription was done using Superscript II (Invitrogen) according to the manufacturer's instructions. Real-time PCRs were carried out using the Mx3005P (Stratagene) in 25 ml of mixture containing equal amounts of cDNA, 1 mM of each primer and 12.5 ml of Sybr Primer pairs used were as follows (5 0 to 3 0 ):
Immunofluorescence U2OS cells grown on cover slips were transfected with plasmids expressing either E1^E4, GFP-E2^E4-S or GFP-E2^E4-L for 24 h. Cover slips were rinsed with PBS and fixed with PBS/2% paraformaldehyde for 1 h in 4 1C. After rehydration, they were permeabilized and saturated with PBS/2% serum/0.1% triton for 30 min at 4 1C. They were then incubated with polyclonal anti-HPV-18 E4 antibody conjugated to Alexa 488 (TVG-405, E1^E4 detection), or analyzed for direct GFP fluorescence (GFP-E2^E4 detection). Nuclei were stained by 4 0 ,6 0 -diamidino-2-phenylindole (DAPI). Pictures were taken with Applied Precision DeltaVision microscope system, and images were analyzed using SoftWoRx v4.0.0.
Clinical samples
The HPV-18 lesion (CINI-II biopsy) as well as the HPV-18 smear cells from 4 different patients with low grade cervical squamous intraepithelial lesions (LSIL) associated with HPV-18, and 1 associated with HPV-58, were collected from NUH (National University Hospital) in Singapore. This work has been approved by the National University of Singapore (NUS) Institutional Review Board (IRB reference code: 09-218, Approval Certificate NUS 827). Individual participants in this study gave written informed consent.
Raft establishment, immunohistochemistry, immunofluorescence and in situ hybridization
We used the plasmid pBS-HPV18WT as a source of HPV-18 DNA (Flores et al., 1999) . Briefly, the viral DNA was excised from the pBS vector by EcoRI and the digestion products were ligated, purified and quantified before transfection. The re-circularized HPV-18 DNA was transfected into NIKS cells as described (Flores et al., 2000; Lambert et al., 2005) . NIKS cells (previously named BC1-Ep/SL cells, a gift from P. Lambert) are a spontaneously immortalized cell line that can differentiate as well as primary keratinocytes . Organotypic raft cultures derived from HPV-18 harboring-NIKS cells were maintained on a dermal equivalent of collagen embedded with human fibroblasts (Neonatal Human Dermal Fibroblasts, CC-2509, Lonza) . Briefly, the cultures were lifted to the liquid-air interface after 4 days in culture and were harvested 14 days post lift as described (Lambert et al., 2005) . The rafts were fixed in 4% formalin, embedded in paraffin, and cut into 5-mm-thick serial sections.
Immunohistochemistry was performed on serial sections of paraffin-embedded rafts or lesions using the Vectastain ABC kit rabbit (Vectastain ABC Kit Rabbit IgG PK-4001, Vector Laboratories). The slides were dewaxed in xylene and rehydrated in a graded series of alcohol washes. After dewaxing, epitope retrieval was performed by heating the sections at 96 1C for 40 min in 10 mM citrate buffer (pH 6.0). After washing in tap water, endogenous peroxidase activity was blocked by incubation in 0.3% hydrogen peroxide for 30 min, and then blocked by incubation in PBS 2% BSA 2% normal goat serum, for 60 min. For immunohistochemistry, primary antibodies (anti-HPV-18 E4, anti-E2 antibodies (Xue et al., 2010) , anti-p16 [clone JC8, Santa Cruz]) were added for 1 h at room temperature and detected using the Vectastain ABC kit as specified by the manufacturer. AEC substrate was added for color revelation. Slides were counterstained with hematoxylin and mounted with Aquatex. For immunofluorescence, anti-HPV-18 E4 antibody conjugated to Alexa 488 (TVG-405) was added together with DAPI for 1 h. The in situ hybridization was performed with the wide spectrum HPV biotinylated DNA probe sets able to detect 11 types of anogenital HPV (In Situ Hybridization System [K0601], Dako) according to manufacturer's instructions.
Propidium iodide uptake
HeLa cells were harvested and immediately labeled with 1 mg/ml propidium iodide (PI) without fixation. They were then subjected to flow cytometry analyses using the LSRII flow cytometer (BD Biosciences). Analyses were performed with the WinMDI software.
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